Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TherapeuticsMD, Inc. Proxy Solicitation & Information Statement 2020

May 4, 2020

35134_rns_2020-05-04_69b3f276-5573-4d10-938b-5e911aba4158.zip

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

DEFA14A 1 txmd-defa14a_061820.htm ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to §240.14a-12

TherapeuticsMD, Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
1) Amount previously paid:
2) Form, Schedule or Registration Statement No.:
3) Filing party:
4) Date Filed:

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

* Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the

Stockholder Meeting to Be Held on June 18, 2020.

THERAPEUTICSMD, INC.

THERAPEUTICSMD, INC. 951 YAMATO ROAD, SUITE 220 BOCA RATON, FL 33431

Meeting Information
Meeting Type: Annual Meeting
For holders as of: April 20, 2020
Date: June 18, 2020 Time: 8:00 a.m., Local Time
Location*:
2000 NW 19th Street Boca Raton, Florida 33431

| *As
part of our precautions regarding the COVID-19 pandemic, we are planning for the possibility that the meeting
may be held only through remote communication. If a decision is made to forego the physical meeting, a news
release will be issued and the information with respect to the logistical details of the meeting, including
how stockholders can remotely access, participate in and vote at the meeting, will be posted on our website,
www.therapeuticsmd.com, and such information will be filed with the U.S. Securities and Exchange Commission
as proxy material, no later than June 8, 2020. |
| --- |
| You
are receiving this communication because you hold shares in the company named above. |
| This is not a ballot. You cannot use this notice to vote these shares.
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You
may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side). |
| We encourage you to access and review all of
the important information contained in the proxy materials before voting. |

See the reverse side of this notice to obtain proxy materials and voting instructions.

D08155-P38133

Field: Page; Sequence: 2

Field: /Page

— Before You Vote —

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT 2019 ANNUAL REPORT

How to View Online:

Have the information that is printed in the box marked by the arrow (located on the following page) and visit: www.proxyvote.com.

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET : www.proxyvote.com
2) BY TELEPHONE : 1-800-579-1639
3) BY E-MAIL *: [email protected]
  • If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 4, 2020 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Vote By Internet: To vote now by Internet, go to www.proxyvote.com . Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions. Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

D08156-P38133

Field: Page; Sequence: 3

Field: /Page

Voting Items

| The
Board of Directors recommends you vote FOR the following: — 1. | Election
of Directors Nominees: 01)
Paul M. Bisaro 02)
J. Martin Carroll 03)
Cooper C. Collins 04)
Robert G. Finizio 05)
Karen L. Ling |
| --- | --- |
| The
Board of Directors recommends you vote FOR the following proposal: | |
| 2. | To
approve, on a non-binding advisory basis, the compensation of our named executive officers
for the fiscal year ended December 31, 2019 (say-on-pay); |
| The Board of Directors recommends you vote FOR the
following proposal: | |
| 3. | To approve an amendment to the
Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock,
$0.001 par value per share, from 350,000,000 shares to 600,000,000 shares; |
| The Board of Directors recommends you vote FOR the
following proposal: | |
| 4. | To approve the TherapeuticsMD,
Inc. 2020 Employee Stock Purchase Plan; |
| The Board of Directors recommends you vote FOR the
following proposal: | |
| 5. | To ratify the appointment of Grant Thornton LLP, an independent
registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2020; |
| and
upon such other business as may properly come before the meeting or any adjournment thereof. | |

D08157-P38133

Field: Page; Sequence: 4

Field: /Page

Field: Rule-Page

Field: /Rule-Page

D08158-P38133

Field: Page; Sequence: 5; Options: Last

Field: /Page